The incidence of obesity in CKD patients has markedly increased over the past decade, and close monitoring of glucose metabolism is advised when initiating GH therapy in these patients owing to an increased risk of impaired glucose tolerance. This evidence concerns the gene GH1 and chronic kidney disease.